17:07 EST NewAmsterdam Pharma (NAMS) files $500M mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress
- NewAmsterdam Pharma price target raised to $52 from $47 at Scotiabank
- Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence
- Promising Outlook for NewAmsterdam Pharma: Buy Rating Affirmed Amid Successful Trials and Strong Financial Position
- Promising Drug Developments and Positive Trial Results Drive Buy Rating for NewAmsterdam Pharma